“Novo Nordisk”

Novo Nordisk names 10 federal bills in 64 lobbying reports this Congress.

• NN

  NOVO NORDISK

  California

• Novo Nordisk

  Indiana

• Novo Nordisk

  Nebraska

• Novo Nordisk

  Florida

• Novo Nordisk

  Oregon

• Novo Nordisk

  Washington

• Novo Nordisk

  Alabama

• Novo Nordisk

  Georgia

• Novo Nordisk

  Nevada

• NOVO NORDISK INC. PAC (NOVO NORDISK PAC)

  District of Columbia · As of Aug 6, 2026

• NN

  NOVO NORDISK INC.

  Congress

• NN

  NOVO NORDISK INC.

  Congress

• NN

  NOVO NORDISK, INC.

  Congress

• NOVO NORDISK BIOCHEM, N.A., INC.

  As of Oct 2, 2026

• Request that the FDA take the following three actions: A) Encourage Novo Nordisk to sign over the FDA rights to manufacture detemir (Levemir) insulin to an organization who will ensure that a biosimilar gets made. This organization could be a non-profit, a contract manufacturer, or other pharmaceutical company to be determined. B) Encourage Novo Nordisk to allow Levemir (detemir) to be purchased

  As of Jun 30, 2026

• Attachment 1 - 16 for Supplement to Citizen Petition from Covington & Burling LLP on behalf of Novo Nordisk Inc.

  As of Sep 23, 2026

• Attachment 1 - 16 for Supplement to Citizen Petition from Covington & Burling LLP on behalf of Novo Nordisk Inc.

  As of Sep 23, 2026

• Attachment 17 - 33 for Supplement to Citizen Petition from Covington & Burling LLP on behalf of Novo Nordisk Inc.

  As of Sep 23, 2026

• Attachment 17 - 33 for Supplement to Citizen Petition from Covington & Burling LLP on behalf of Novo Nordisk Inc.

  As of Sep 23, 2026

• Attachment 34 - 53 for Supplement to Citizen Petition from Covington & Burling LLP on behalf of Novo Nordisk Inc.

  As of Sep 23, 2026

• Attachment 34 - 53 for Supplement to Citizen Petition from Covington & Burling LLP on behalf of Novo Nordisk Inc.

  As of Sep 23, 2026

• Attachment 54 - 65 for Supplement to Citizen Petition from Covington & Burling LLP on behalf of Novo Nordisk Inc.

  As of Sep 23, 2026

• Attachment 54 - 65 for Supplement to Citizen Petition from Covington & Burling LLP on behalf of Novo Nordisk Inc.

  As of Sep 23, 2026